Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 42 for:    "Buffalo" AND "Singh"

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03203304
Recruitment Status : Recruiting
First Posted : June 29, 2017
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
External beam photon stereotactic body radiotherapy (SBRT) using a linear accelerator to a total dose of 40 Gy in 5 fractions delivered once daily with at least 48 hours between each fraction. SBRT treatment will be completed within a 21-day window. Starting within 14 days after completion of SBRT, intravenous nivolumab 240 mg will be given every 2 weeks as monotherapy or in combination with ipilimumab 1 mg/kg IV every 6 weeks.

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Drug: Nivolumab Drug: Ipilimumab Phase 1

Detailed Description:

1.1 Primary Objective & Hypothesis Determine the safety and tolerability of SBRT followed by nivolumab or ipilimumab with nivolumab for hepatocellular carcinoma by establishing the rates of toxicity that occur within 6 months from start of SBRT. Hypothesis: SBRT followed by nivolumab or nivolumab and ipilimumab will have similar toxicity to historical controls of SBRT or nivolumab monotherapy.

1.2 Secondary Objectives and Hypotheses Estimate the investigator determined best overall response rate. Hypothesis: Combining radiation and nivolumab or nivolumab and ipilimumab will improve the best overall response rate compared to historical controls with SBRT or nivolumab alone.

Estimate the rates of long-term adverse events (after 6 months) from the end of SBRT. Hypothesis: Long-term toxicity from SBRT with nivolumab or nivolumab and ipilimumab will be comparable to that observed with nivolumab monotherapy.

Summarize the distant disease control, progression-free survival, and overall survival. Hypothesis: Disease control and survival will be comparable to (or better than) that observed with nivolumab monotherapy.

Summarize the local control of the SBRT treated lesion. Hypothesis: Combining SBRT and nivolumab or nivolumab and ipilimumab will have similar (or better) local control rates as observed in SBRT only series.

1.3 Exploratory Objectives Explore changes in inflammatory biomarkers (including, but not limited to CD8/Treg ratio, total CD4 counts, total lymphocyte count) in pretreatment and on-treatment serially collected peripheral blood samples. Hypothesis: Changes in inflammatory biomarkers after radiation therapy may correlate with a more favorable response to immunotherapy.

Explore changes in the tumor microenvironment induced by radiation on pre and post treatment biopsies. Hypothesis: Changes in the tumor microenvironment after radiation therapy will be observed that may correlate with a more favorable response to immunotherapy.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma
Actual Study Start Date : August 25, 2017
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab

Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.

After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation.

Drug: Nivolumab
240mg every two weeks by IV infusion
Other Name: Opdivo

Experimental: Nivolumab and ipilimumab

Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.

After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks.

Drug: Nivolumab
240mg every two weeks by IV infusion
Other Name: Opdivo

Drug: Ipilimumab
1mg/kg every six weeks by IV infusion
Other Name: Yervoy




Primary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: 3 years ]
    To determine the safety and tolerability of SBRT followed by nivolumab or ipilimumab with nivolumab for hepatocellular carcinoma by establishing the rates of toxicity that occur within 6 months from start of SBRT by analyzing the number of patients with adverse events.


Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: 3 years ]
    Estimate the investigator determined best overall response rate.

  2. Number of long-term adverse events [ Time Frame: from date of randomization until the date of last documented adverse event or date of death from any cause, whichever comes first, up to 100 months ]
    Estimate the rates of long-term adverse events (after 6 months) from the end of SBRT.

  3. Time to progression free survival [ Time Frame: from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, up to 100 months ]
  4. Time of overall survival [ Time Frame: from date of randomization until the date of death from any cause, whichever comes first, up to 100 months ]
  5. Rate of disease control [ Time Frame: from date of randomization until the date of death from any cause, whichever comes first, up to 100 months ]
  6. Rate of local control of the SBRT treated lesion [ Time Frame: from date of randomization until the date of death from any cause, whichever comes first, up to 100 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be willing and able to provide written informed consent for the trial.
  • Be ≥ 18 years of age on day of signing informed consent.
  • Have ECOG performance status 0-1.
  • Pretreatment CT chest /abdomen /pelvis within 28 days of protocol enrollment.
  • Pathologic diagnosis of hepatocellular carcinoma (including fibrolamellar variants and biphenotypic tumors with an HCC component).
  • Child Pugh Class A (score = 5 or 6)cirrhosis (assessed within 14 days of SBRT)
  • Deemed ineligible for curative intent therapy with surgical resection or liver transplantation.
  • Patients with diffuse/multifocal liver involvement are eligible.
  • Patients with extrahepatic disease are eligible.
  • Prior systemic therapies for HCC are allowed but not required.
  • Must have at least one intrahepatic lesion amenable to SBRT.
  • Prior transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) allowed, however, patient must have separate intrahepatic lesion amenable to SBRT and biopsy.
  • Intrahepatic lesion amenable to pre and post SBRT biopsies, unless the investigator determines that the tumor biopsies would be unsafe.
  • Have measurable disease based on RECIST 1.1.
  • Demonstrate adequate organ function as defined in Table 1. All screening labs should be performed within 14 days of treatment initiation.

Table 1 - Adequate Organ Function Laboratory Values System Laboratory Value Hematological Platelets ≥ 40,000 / mcL Hepatic Serum total bilirubin ≤ 3 mg/dL AST (SGOT) and ALT (SGPT) ≤ 5 X ULN

  • Negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication for female subjects of childbearing age.
  • Subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 150 days after the last dose of study therapy (for women of child-bearing potential) or 210 days after the last dose of study therapy (for men who have partners of child-bearing potential).
  • Have a life expectancy of greater than 6 months (in the opinion of the treating physician).

Exclusion Criteria:

  • Prior external beam radiation therapy to the liver (defined as > 1 Gy).
  • Prior yttrium-90 radioembolization treatment.
  • Patients with HBV viral load > 100 IU/mL (antiviral therapy per local practice is required).
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at a dose of >10 mg prednisone daily or equivalent at time of first dose of trial treatment.
  • Has a known history of active TB (Bacillus Tuberculosis).
  • Hypersensitivity to nivolumab or ipilimumab or any of its excipients.
  • Has had prior anticancer therapy within 4 weeks of study Day 1 or has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  • Has a known additional malignancy that is progressing or requires active treatment.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with allografts (including liver transplants) are not eligible for this protocol.
  • Has known history of, or any evidence of active, non-infectious pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
  • Has received a live vaccine within 30 days of planned start of study therapy.
  • Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03203304


Contacts
Layout table for location contacts
Contact: Chih-Yi Liao, MD 773-702-6241 andyliao@medicine.bsd.uchicago.edu
Contact: Jaclyn Peterson, MBA jdpeterson@medicine.bsd.uchicago.edu

Locations
Layout table for location information
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Jackie Peterson    773-834-1746    jdpeterson@medicine.bsd.uchicago.edu   
United States, New York
Roswell Park Cancer Institute Not yet recruiting
Buffalo, New York, United States, 14263
Contact: Renuka Iyer, MD    716-845-2300      
Contact: Anurag Singh, MD    7168452300      
United States, Wisconsin
Medical College of Wisconsin Not yet recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Ben George, MD    414-805-0505      
Contact: Jared Robbins, MD    (414) 805-4477      
Sponsors and Collaborators
University of Chicago
Investigators
Layout table for investigator information
Principal Investigator: Chih-Yi Liao, MD University of Chicago

Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT03203304     History of Changes
Other Study ID Numbers: IRB17-0578
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Chicago:
hepatocellular carcinoma
nivolumab
ipilimumab
stereotactic body radiotherapy
SBRT

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents